Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
Jones DA. et al, (2024), Br J Haematol
Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol), 35, 301 - 310
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
Jones D. et al, (2022), HemaSphere, 6, 43 - 44
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.
Jones DA. et al, (2022), Blood Adv, 6, 909 - 919
A Systematic Review of Health Economic Evaluations of Proton Beam Therapy for Adult Cancer: Appraising Methodology and Quality
GRAY A. et al, (2019), Clinical and Translational Radiation Oncology
A Systematic Review of Health Economic Evaluations of Proton Beam Therapy for Adult Cancer: Appraising Methodology and Quality
JONES D. et al, (2019), Clinical and Translational Radiation Oncology
Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
GRAY A. and JONES D., (2019), European Journal of Cancer
1111OCisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)
Jones DA. et al, (2019), Annals of Oncology, 30
Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV plus OPC)
Jones DA. et al, (2019), ANNALS OF ONCOLOGY, 30
Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.
Kong AH. et al, (2019), Journal of Clinical Oncology, 37, 6076 - 6076